Free Trial

Seres Therapeutics (NASDAQ:MCRB) Shares Cross Above 50-Day Moving Average - Here's Why

Seres Therapeutics logo with Medical background

Key Points

  • Seres Therapeutics' stock price has recently crossed above its 50-day moving average of $16.35, achieving a high of $18.78 before last trading at $17.45.
  • The company reported a quarterly loss of ($2.27) EPS, which beat analysts' expectations of ($2.72) EPS.
  • Institutional investors, including Millennium Management LLC and Invesco Ltd., have shown significant interest, with hedge funds and institutions owning 59.34% of the company's stock.
  • MarketBeat previews the top five stocks to own by November 1st.

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report)'s share price crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $16.35 and traded as high as $18.78. Seres Therapeutics shares last traded at $17.45, with a volume of 205,420 shares changing hands.

Seres Therapeutics Stock Performance

The stock's 50-day simple moving average is $16.39 and its 200-day simple moving average is $12.29. The firm has a market capitalization of $144.64 million, a PE ratio of -3.61 and a beta of 0.15.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported ($2.27) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.72) by $0.45. As a group, analysts predict that Seres Therapeutics, Inc. will post -0.38 earnings per share for the current fiscal year.

Institutional Trading of Seres Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of MCRB. Jane Street Group LLC grew its position in shares of Seres Therapeutics by 181.4% in the 4th quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company's stock worth $49,000 after buying an additional 37,866 shares during the period. SBI Securities Co. Ltd. grew its position in shares of Seres Therapeutics by 221.8% in the 1st quarter. SBI Securities Co. Ltd. now owns 69,664 shares of the biotechnology company's stock worth $49,000 after buying an additional 48,013 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Seres Therapeutics by 40.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company's stock worth $52,000 after buying an additional 21,679 shares during the period. Invesco Ltd. grew its position in shares of Seres Therapeutics by 193.2% in the 1st quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company's stock worth $96,000 after buying an additional 89,995 shares during the period. Finally, Northern Trust Corp grew its position in shares of Seres Therapeutics by 20.4% in the 4th quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company's stock worth $218,000 after buying an additional 44,461 shares during the period. 59.34% of the stock is owned by hedge funds and other institutional investors.

About Seres Therapeutics

(Get Free Report)

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.

See Also

Should You Invest $1,000 in Seres Therapeutics Right Now?

Before you consider Seres Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seres Therapeutics wasn't on the list.

While Seres Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.